Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The cardiomyocyte cell cycle.

Pascal J E Lafontant1, Loren J Field

  • 1Wells Center for Pediatric Research and Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN 46202-5225, USA.

Novartis Foundation Symposium
|October 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Musings on intrinsic cardiomyocyte cell cycle activity and myocardial regeneration.

Journal of molecular and cellular cardiology·2023
Same author

Cardiac Troponin I-Interacting Kinase Affects Cardiomyocyte S-Phase Activity but Not Cardiomyocyte Proliferation.

Circulation·2022
Same author

Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase.

Science (New York, N.Y.)·2022
Same author

Cardioprotection vs. regeneration: the case of extracellular vesicle-derived microRNAs.

Basic research in cardiology·2021
Same author

Genetic ablation of Cullin-RING E3 ubiquitin ligase 7 restrains pressure overload-induced myocardial fibrosis.

PloS one·2020
Same author

Complex Arrhythmia Syndrome in a Knock-In Mouse Model Carrier of the N98S <i>Calm1</i> Mutation.

Circulation·2020
Same journal

Genetic and therapeutic control of diabetogenic CD8+ T cells.

Novartis Foundation symposium·2009
Same journal

Translating mucosal antigen based prevention of autoimmune diabetes to human.

Novartis Foundation symposium·2009
Same journal

Re-establishing immune tolerance in type 1 diabetes via regulatory T cells.

Novartis Foundation symposium·2009
Same journal

Immune markers of disease and therapeutic intervention in type 1 diabetes.

Novartis Foundation symposium·2009
Same journal

Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.

Novartis Foundation symposium·2009
Same journal

CD8 and cytotoxic T cells in type 1 diabetes.

Novartis Foundation symposium·2009
See all related articles

Promoting cardiomyocyte cell cycle activity aids heart regeneration after injury. Strategies like manipulating p193 or cyclin D2 can increase cardiomyocyte numbers and reduce infarct size, offering a regenerative approach for cardiac repair.

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Molecular Cardiology

Background:

  • Cardiac diseases often lead to cardiomyocyte death via necrosis, apoptosis, or oncosis.
  • Cardiac regeneration is a promising strategy to replace damaged heart tissue.
  • Stimulating cardiomyocyte cell cycle activity in surviving heart muscle is a key approach for regeneration.

Purpose of the Study:

  • To investigate methods for promoting cardiomyocyte cell cycle activity for cardiac regeneration.
  • To evaluate the efficacy of genetic modifications in stimulating cardiomyocyte proliferation in damaged hearts.

Main Methods:

  • Utilized genetically modified mouse models to study cardiomyocyte proliferation.
  • Investigated the effects of expressing a dominant-interfering version of p193 (Cul7) in a heart-restricted manner.

Related Experiment Videos

  • Examined the impact of targeted cyclin D2 expression in adult mouse hearts post-myocardial infarction.

    • Main Results:

    • Expression of p193 induced cardiomyocyte cell cycle activity at the infarct border zone and septum, reducing hypertrophic growth.
    • Targeted cyclin D2 expression increased cardiomyocyte cell cycle activity post-myocardial infarction.
    • Both interventions led to increased cardiomyocyte numbers and reduced infarct size, suggesting regenerative potential.

    Conclusions:

    • Modulating cardiomyocyte cell cycle activity is a viable strategy for promoting regenerative growth in injured hearts.
    • Genetic manipulation of specific pathways (e.g., p193, cyclin D2) can enhance cardiac repair post-infarction.
    • Activating cardiomyocyte proliferation offers a potential therapeutic avenue to counteract adverse ventricular remodeling.